BerandaIMGN • BMV
add
ImmunoGen Ord Shs
Tutup sebelumnya
$268,50
Rentang tahun
$268,50 - $268,50
Kapitalisasi pasar
8,72 M USD
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Sep 2023info | Perubahan Y/Y |
---|---|---|
Pendapatan | 113,42 jt | 637,72% |
Biaya operasional | 37,74 jt | 12,26% |
Laba bersih | 30,75 jt | 139,54% |
Margin laba bersih | 27,11 | 105,36% |
Penghasilan per saham | 0,10 | 132,26% |
EBITDA | 26,38 jt | 134,26% |
Tarif pajak efektif | -3,94% | — |
Neraca
Total aset
Total liabilitas
(USD) | Sep 2023info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 605,54 jt | 95,64% |
Total aset | 822,10 jt | 129,13% |
Total liabilitas | 260,50 jt | 44,09% |
Total ekuitas | 561,60 jt | — |
Saham yang beredar | 266,26 jt | — |
Harga terhadap nilai buku | 127,25 | — |
Tingkat pengembalian aset | 8,45% | — |
Tingkat pengembalian modal | 10,17% | — |
Arus Kas
Perubahan kas bersih
(USD) | Sep 2023info | Perubahan Y/Y |
---|---|---|
Laba bersih | 30,75 jt | 139,54% |
Kas dari operasi | 2,77 jt | 104,31% |
Kas dari investasi | -1,35 jt | -124,92% |
Kas dari pembiayaan | 32,13 jt | 7.056,35% |
Perubahan kas bersih | 33,55 jt | 152,12% |
Arus kas bebas | -2,32 jt | 91,72% |
Tentang
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for $10.1 billion. Wikipedia
Didirikan
1981
Kantor pusat
Situs
Karyawan
277